Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
Elevai Labs, Inc. (NASDAQ: ELAB) has announced positive results from a clinical study of its Elevai enfinity™ topical exosome serum. The 12-week study, conducted on 29 participants aged 40-70 with mild to moderate facial photoaging and sensitive skin, showed the product to be safe and tolerable with significant improvements in various aspects of skin appearance.
The study, led by renowned dermatologist Dr. Zoe Draelos, assessed the twice-daily use of Elevai enfinity™ on facial firmness, skin tone, wrinkles, and smoothness. CEO Dr. Jordan R. Plews emphasized the importance of this rigorous study in validating the product's effectiveness. Elevai plans to publish the full study results soon and continues to prioritize scientific research as part of its commercial strategy for 2024 and beyond.
Elevai Labs, Inc. (NASDAQ: ELAB) ha annunciato risultati positivi da uno studio clinico sul suo siero topico di esomi Elevai enfinity™. Lo studio di 12 settimane, condotto su 29 partecipanti di età compresa tra 40 e 70 anni con foto-invecchiamento facciale da lieve a moderato e pelle sensibile, ha dimostrato che il prodotto è sicuro e tollerabile con significativi miglioramenti in vari aspetti dell'aspetto cutaneo.
Lo studio, guidato dalla rinomata dermatologa Dr. Zoe Draelos, ha valutato l'uso del siero Elevai enfinity™ due volte al giorno sulla fermezza del viso, il tono della pelle, le rughe e la morbidezza. Il CEO Dr. Jordan R. Plews ha sottolineato l'importanza di questo rigoroso studio per convalidare l'efficacia del prodotto. Elevai prevede di pubblicare presto i risultati completi dello studio e continua a dare priorità alla ricerca scientifica come parte della sua strategia commerciale per il 2024 e oltre.
Elevai Labs, Inc. (NASDAQ: ELAB) ha anunciado resultados positivos de un estudio clínico sobre su suero tópico de exosomas Elevai enfinity™. El estudio de 12 semanas, realizado en 29 participantes de entre 40 y 70 años con fotoenvejecimiento facial leve a moderado y piel sensible, demostró que el producto es seguro y tolerable, mostrando mejoras significativas en varios aspectos de la apariencia de la piel.
El estudio, liderado por la renombrada dermatóloga Dr. Zoe Draelos, evaluó el uso del Elevai enfinity™ dos veces al día respecto a la firmeza facial, el tono de la piel, las arrugas y la suavidad. El CEO Dr. Jordan R. Plews enfatizó la importancia de este riguroso estudio para validar la efectividad del producto. Elevai planea publicar pronto los resultados completos del estudio y continúa priorizando la investigación científica como parte de su estrategia comercial para 2024 y más allá.
Elevai Labs, Inc. (NASDAQ: ELAB)는 자사의 Elevai enfinity™ 국소 엑소좀 세럼에 대한 임상 연구에서 긍정적인 결과를 발표했습니다. 12주 동안 진행된 이 연구는 40세에서 70세 사이의 경증에서 중등도의 얼굴 광노화 및 민감한 피부를 가진 29명의 참가자를 대상으로 하여, 제품이 안전하고 잘 견딜 수 있는 것으로 나타나고 피부 외관의 여러 측면에서 유의미한 개선이 있음을 보여주었습니다.
저명한 피부과 의사인 Dr. Zoe Draelos가 이끈 이번 연구는 Elevai enfinity™를 하루 두 번 사용했을 때 얼굴의 탄력성, 피부 톤, 주름 및 매끄러움에 미치는 영향을 평가했습니다. CEO인 Dr. Jordan R. Plews는 제품의 효능을 검증하는 데 있어 이 엄격한 연구의 중요성을 강조했습니다. Elevai는 곧 전체 연구 결과를 발표할 예정이며, 2024년 및 그 이후의 상업 전략의 일환으로 과학 연구를 우선시할 것입니다.
Elevai Labs, Inc. (NASDAQ: ELAB) a annoncé des résultats positifs d'une étude clinique sur son sérum topique d'exosomes Elevai enfinity™. L'étude de 12 semaines, menée auprès de 29 participants âgés de 40 à 70 ans présentant un photovieillissement facial léger à modéré et une peau sensible, a montré que le produit était sans danger et tolérable avec des améliorations significatives dans divers aspects de l'apparence de la peau.
L'étude, dirigée par la célèbre dermatologue Dr. Zoe Draelos, a évalué l'utilisation d'Elevai enfinity™ deux fois par jour en ce qui concerne la fermeté du visage, le teint, les rides et la douceur. Le PDG Dr. Jordan R. Plews a souligné l'importance de cette étude rigoureuse pour valider l'efficacité du produit. Elevai prévoit de publier bientôt les résultats complets de l'étude et continue de donner la priorité à la recherche scientifique dans le cadre de sa stratégie commerciale pour 2024 et au-delà.
Elevai Labs, Inc. (NASDAQ: ELAB) hat positive Ergebnisse aus einer klinischen Studie zu seinem Elevai enfinity™ topischen Exosomenserum bekannt gegeben. Die 12-wöchige Studie, die an 29 Teilnehmern im Alter von 40 bis 70 Jahren mit mildem bis mäßigem Gesichtsfotoalterung und empfindlicher Haut durchgeführt wurde, zeigte, dass das Produkt sicher und verträglich ist und signifikante Verbesserungen in verschiedenen Aspekten des Hautbildes aufweist.
Die Studie, die von der renommierten Dermatologin Dr. Zoe Draelos geleitet wurde, bewertete die zweimal tägliche Anwendung von Elevai enfinity™ hinsichtlich der Gesichtsstraffung, des Hauttons, von Falten und von Geschmeidigkeit. CEO Dr. Jordan R. Plews betonte die Bedeutung dieser rigorosen Studie zur Validierung der Wirksamkeit des Produkts. Elevai plant, bald die vollständigen Studienergebnisse zu veröffentlichen und setzt weiterhin wissenschaftliche Forschung als Teil seiner kommerziellen Strategie für 2024 und darüber hinaus an erste Stelle.
- Completed clinical study shows Elevai enfinity™ to be safe and tolerable
- Significant improvements noted in various aspects of skin appearance
- Collaboration with renowned dermatologist Dr. Zoe Draelos adds credibility to the study
- Plans to publish full study results, enhancing transparency
- Ongoing studies to support clinical validation of Elevai's proprietary exosomes
- None.
Insights
The completion of Elevai's clinical study on Elevai enfinity™ topical exosome serum marks a significant milestone in the field of regenerative aesthetics. With 29 participants over a 12-week period, the study's scope is modest but promising. The reported improvements in facial firmness, skin tone, wrinkles and smoothness are encouraging, but without specific data, it's challenging to gauge the magnitude of these effects.
The involvement of Dr. Zoe Draelos, a respected dermatologist with extensive research experience, lends credibility to the study. However, it's important to note that the results are still pending peer review, which is the gold standard for scientific validation. The focus on subjects with sensitive skin and mild to moderate photoaging is particularly interesting, as it addresses a common demographic in the skincare market.
While the news is positive, investors should await the full published results to understand the true impact and potential market positioning of Elevai enfinity™ in the competitive exosome-based skincare landscape.
Elevai's strategic focus on scientific validation in the rapidly growing exosome-based skincare market is noteworthy. By prioritizing clinical studies, the company is positioning itself to stand out in an increasingly crowded field. The emphasis on safety and tolerability, alongside efficacy, addresses key concerns in the adoption of new skincare technologies.
The 8-in-1 serum approach of Elevai enfinity™ could be a unique selling point, potentially offering a simplified skincare routine for consumers. However, the true market impact will depend on how the product's results compare to existing solutions and other exosome-based products.
The endorsement from Dr. Calobrace, a top customer and plastic surgeon, suggests potential for strong adoption in professional channels. This could be a significant advantage for Elevai, as professional recommendations often drive consumer choices in high-end skincare.
Investors should monitor how Elevai leverages these clinical results in its marketing and distribution strategies, as well as any follow-up studies that could further differentiate the product in the market.
NEWPORT BEACH, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Elevai Labs, Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance. The data, pending peer review, from the clinical study was internally reviewed by the Company, and the results show Elevai enfinity™ to be safe and tolerable with significant improvement noted across many aspects of skin appearance. Elevai aims to publish the full study results in the near future.
The study assessed the use of twice-daily Elevai enfinity™, a topical exosome product, on 29 study participants over a 12-week period, to determine the efficacy on facial appearance, including measurements like facial firmness, skin tone, wrinkles and smoothness. The study investigated healthy subjects between 40-70 years of age with mild to moderate facial photoaging and sensitive skin.
Elevai worked with Dr. Zoe Draelos, a board-certified dermatologist as the Principal Investigator. Renowned for her extensive experience with research in aesthetics and cosmetics, Dr. Draelos brings 35 years of dermatology experience leading over 800 clinical studies.
“We were fortunate to collaborate with Dr. Draelos in conducting this pivotal clinical study on behalf of Elevai,” remarked Dr. Jordan R. Plews, PhD, Chief Executive Officer of Elevai Skincare Inc. “As a company that places science at the forefront of our mission, we recognized the significance of rigorously designing a study to validate the safety, effectiveness and tolerability of our daily topical exosome serum, Elevai enfinity™.”
Elevai enfinity™ harnesses the power of potent next generation stem cell technology and scientifically proven ingredients creating an 8-in-1 serum. Elevai enfinity™ leverages exosomes that work at a cellular level to support the skin’s natural repair mechanisms, giving skin a radiant and more youthful complexion.
With the recent entrance and expanding landscape of topical exosomes into the aesthetic skincare space, there has been a call for more scientific research examining the safety and tolerability of exosomes in addition to their effectiveness at improving the appearance of common skin-aging effects. Elevai is poised to prioritize science and data as part of the commercial strategy for 2024 onward, leveraging clinical results as a vital point of differentiation versus competing exosome products. The Draelos clinical study will be the first study Elevai Skincare plans to publish, with ongoing studies supporting the clinical validation of Elevai’s proprietary exosomes.
M. Bradley Calobrace, MD, FACS, a leading rejuvenation expert and top customer of Elevai enfinity™ stated:
“As a plastic surgeon, I believe it is imperative to see clinical evidence and data to fully understand the potential of topical exosome technology and how we can use it to best benefit our patients. We look forward to seeing more clinical validation studies from Elevai in the future as this regenerative aesthetics category continues to expand and we see more demand from our patients seeking out this innovative approach to skincare.”
About Elevai Labs Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit www.elevailabs.com.
About Elevai Skincare Inc.
Elevai Skincare Inc., a subsidiary of Elevai Labs Inc., is a medical aesthetics company developing and commercializing cutting-edge physician-dispensed skin and hair care applications. Elevai Skincare Inc. develops cosmetic products for the physician-dispensed market, with a focus on leveraging novel proprietary science-backed technologies, including its stem cell exosome technology. For more information, please visit www.elevaiskincare.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: Elevai’s limited operating history and historical losses; Elevai’s ability to raise additional funding to complete the development and any commercialization of its product candidates; Elevai’s dependence on the success of its product candidates EL-22 and EL-32; that Elevai may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; Elevai’s ability to obtain, maintain and protect its intellectual property; Elevai’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies; and Elevai’s expectations regarding its growth, strategy, progress and the design, objectives and timing of its studies.
These and other risks are described more fully in Elevai Labs’ filings with the Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Relations Contact:
Makenzie Mann
contact@elevailabs.com
FAQ
What were the results of Elevai Labs' clinical study on Elevai enfinity™ (ELAB)?
How long did the Elevai Labs (ELAB) clinical study for Elevai enfinity™ last?
Who was the principal investigator for Elevai Labs' (ELAB) clinical study on Elevai enfinity™?
What is Elevai Labs' (ELAB) strategy for differentiating Elevai enfinity™ in the market?
